Dendritic cell transfer for cancer immunotherapy.

Abstract

Dendritic cells (DCs) play a major role in cancer immunosurveillance as they bridge innate and adaptive immunity by detecting tumor-associated antigens and presenting them to T lymphocytes. The adoptive transfer of antigen loaded DCs has been proposed as an immunotherapeutic approach for the treatment of various types of cancer. Nevertheless, despite promising preclinical data, the therapeutic efficacy of DC transfer is still deceptive in cancer patients. Here we summarize recent findings in DC biology with a special focus on the development of actionable therapeutic strategies and discuss experimental and clinical approaches that aim at improving the efficacy of DC-based immunotherapies, including, but not limited to, optimized DC production and antigen loading, stimulated maturation, the co-treatment with additional immunotherapies, as well as the inhibition of DC checkpoints.

• Authors: Liwei Zhao, Shuai Zhang, Oliver Kepp, Guido Kroemer, Peng Liu
• Journal: International review of cell and molecular biology (Int Rev Cell Mol Biol) Vol. 370 Pg. 33-64 ( 2022) ISSN: 1937-6448 [Print] Netherlands
• PMID: 35798506 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Antigens, Neoplasm
• Cancer Vaccines

Topics

• Antigens, Neoplasm (metabolism)
• Cancer Vaccines
• Dendritic Cells
• Humans
• Immunotherapy
• Neoplasms (metabolism)
• T-Lymphocytes